Parkinson's disease/Parkinson syndromes?excitatory amino acids

1992 ◽  
Vol 7 (S1) ◽  
pp. 68-70
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Excitatory Amino Acids

Excitatory amino acids and Parkinson's disease

1990 ◽  
Vol 13 (2) ◽  
pp. 46 ◽  
Author(s):  
Werner J. Schmidt ◽  
Michael Bubser ◽  
Wolfgang Hauber
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Excitatory Amino Acids

Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson’s disease

2014 ◽  
Vol 122 (3) ◽  
pp. 411-417 ◽  
Author(s):  
Qing Tong ◽  
Qinrong Xu ◽  
Qiang Xia ◽  
Yongsheng Yuan ◽  
Li Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Plasma Levels ◽  
Nonmotor Symptoms

scholarly journals A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease

2019 ◽  
Vol 116 (15) ◽  
pp. 7419-7424 ◽  
Author(s):  
Jill A. Hollenbach ◽  
Paul J. Norman ◽  
Lisa E. Creary ◽  
Vincent Damotte ◽  
Gonzalo Montero-Martin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Molecular Model ◽  
Peptide Binding ◽  
Smoking History ◽  
Disease Predisposition ◽  
History Of

Parkinson’s disease (PD) is a neurodegenerative disease in which genetic risk has been mapped to HLA, but precise allelic associations have been difficult to infer due to limitations in genotyping methodology. Mapping PD risk at highest possible resolution, we performed sequencing of 11 HLA genes in 1,597 PD cases and 1,606 controls. We found that susceptibility to PD can be explained by a specific combination of amino acids at positions 70–74 on the HLA-DRB1 molecule. Previously identified as the primary risk factor in rheumatoid arthritis and referred to as the “shared epitope” (SE), the residues Q/R-K/R-R-A-A at positions 70–74 in combination with valine at position 11 (11-V) is highly protective in PD, while risk is attributable to the identical epitope in the absence of 11-V. Notably, these effects are modified by history of cigarette smoking, with a strong protective effect mediated by a positive history of smoking in combination with the SE and 11-V (P = 10−4; odds ratio, 0.51; 95% confidence interval, 0.36–0.72) and risk attributable to never smoking in combination with the SE without 11-V (P = 0.01; odds ratio, 1.51; 95% confidence interval, 1.08–2.12). The association of specific combinations of amino acids that participate in critical peptide-binding pockets of the HLA class II molecule implicates antigen presentation in PD pathogenesis and provides further support for genetic control of neuroinflammation in disease. The interaction of HLA-DRB1 with smoking history in disease predisposition, along with predicted patterns of peptide binding to HLA, provide a molecular model that explains the unique epidemiology of smoking in PD.

Tyrosine-fortified silk amino acids improve physical function of Parkinson’s disease rats

2011 ◽  
Vol 20 (1) ◽  
pp. 79-84 ◽  
Author(s):  
Tae Kyun Kim ◽  
Dongsun Park ◽  
Seongho Yeon ◽  
Sun Hee Lee ◽  
Young Jin Choi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Physical Function

Free amino acids in the brain of patients with Parkinson's disease

1988 ◽  
Vol 94 (1-2) ◽  
pp. 182-186 ◽  
Author(s):  
Juha O. Rinne ◽  
Toivo Halonen ◽  
Paavo J. Riekkinen ◽  
Urpo K. Rinne
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Free Amino Acids ◽  
Free Amino ◽  
The Brain

scholarly journals C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease

2019 ◽  
Vol 294 (25) ◽  
pp. 9973-9984 ◽  
Author(s):  
Ryan P. McGlinchey ◽  
Shannon M. Lacy ◽  
Katherine E. Huffer ◽  
Nahid Tayebi ◽  
Ellen Sidransky ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Amyloid Fibrils ◽  
Lewy Bodies ◽  
Amyloid Formation ◽  
Pathological Feature ◽  
Cysteine Cathepsins ◽  
Cathepsin Activity ◽  
Cysteine Cathepsin

A pathological feature of Parkinson's disease (PD) is Lewy bodies (LBs) composed of α-synuclein (α-syn) amyloid fibrils. α-Syn is a 140 amino acids–long protein, but truncated α-syn is enriched in LBs. The proteolytic processes that generate these truncations are not well-understood. On the basis of our previous work, we propose that these truncations could originate from lysosomal activity attributable to cysteine cathepsins (Cts). Here, using a transgenic SNCAA53T mouse model, overexpressing the PD-associated α-syn variant A53T, we compared levels of α-syn species in purified brain lysosomes from nonsymptomatic mice with those in age-matched symptomatic mice. In the symptomatic mice, antibody epitope mapping revealed enrichment of C-terminal truncations, resulting from CtsB, CtsL, and asparagine endopeptidase. We did not observe changes in individual cathepsin activities, suggesting that the increased levels of C-terminal α-syn truncations are because of the burden of aggregated α-syn. Using LC-MS and purified α-syn, we identified C-terminal truncations corresponding to amino acids 1–122 and 1–90 from the SNCAA53T lysosomes. Feeding rat dopaminergic N27 cells with exogenous α-syn fibrils confirmed that these fragments originate from incomplete fibril degradation in lysosomes. We mimicked these events in situ by asparagine endopeptidase degradation of α-syn fibrils. Importantly, the resulting C-terminally truncated fibrils acted as superior seeds in stimulating α-syn aggregation compared with that of the full-length fibrils. These results unequivocally show that C-terminal α-syn truncations in LBs are linked to Cts activities, promote amyloid formation, and contribute to PD pathogenesis.

Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson’s disease: review and meta‐analysis

2020 ◽  
Vol 27 (11) ◽  
pp. 2336-2347 ◽  
Author(s):  
F. J. Jiménez‐Jiménez ◽  
H. Alonso‐Navarro ◽  
E. García‐Martín ◽  
J. A. G. Agúndez
Keyword(s):  
Parkinson’S Disease ◽  
Amino Acids ◽  
Parkinson's Disease ◽  
Meta Analysis ◽  
Blood Levels ◽  
Potential Biomarkers
Sign in / Sign up

Export Citation Format

Share Document